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Abstract
Pertussis, more commonly known as whooping cough, is a potentially fatal respiratory
disease caused by Bordetella pertussis. Two different types of vaccines provide effective
protection: killed whole-cell vaccines (wPV) and more recently available acellular vaccines
(aPVs) formulated with specific components. Disturbingly, while the vaccines are widely
used, the incidence of disease is increasing in several developed countries that have
switched from wPV to an aPV. It is suggested that the single most important underlying
cause suggested for the resurgence is transmission through asymptomatic infections.
While both vaccines protect against disease, a newly developed baboon model has shown
that they do not prevent infection. Importantly, wPV-vaccinated animals appeared to clear
an infection more rapidly than those vaccinated with aPV, which can relate to the period
of possible disease transmission. To ultimately control whooping cough, it is clear that a
more effective vaccine is needed that can prevent both disease and transmission. Modifi-
cations underway include the elimination of LPS from wPVs to improve their safety
profiles and augmentation of aPVs with other bacterium proteins to increase immunoge-
nicity and the longevity of protection. In the interim, vaccinations with aPV during
pregnancy appear to protect newborns, the most susceptible to deadly pertussis.
Keywords: pertussis, whooping cough, whole-cell vaccine, acellular vaccine,
herd protection
1. Introduction
Pertussis or whooping cough, caused by Bordetella pertussis, is a severe respiratory childhood
disease that can be fatal, particularly in very young infants. However, it also represents a
significant disease burden in older children, adolescents, and adults [1]. The first pertussis
vaccine was developed in 1926 [2] but has only been available for large-scale administration
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since the middle of the last century. Today, more efficacious vaccines based on key antigens of
pertussis have been developed and are available for providing global coverage in vaccination
programs [3]. These vaccines are included on the World Health Organization (WHO) Model
List of Essential Medicines, as one of the most effective and safe medicines needed in a
healthcare system [4]. Nevertheless, the disease is still not under control and today is consid-
ered one of the most prevalent vaccine-preventable childhood diseases. The World Health
Organization (WHO) records close to 160,700 pertussis-related deaths in children younger
than 5 years in 2014 and more than 24.1 million yearly pertussis cases worldwide [5]. Since
the 1950s, the incidence and the numbers of pertussis-linked deaths have declined dramati-
cally and reached its lowest point in several countries in the late 1970s, which showed the
effectiveness of mass vaccination programs against pertussis. Prior to their implementation,
the reported incidence of the disease was as high as 150 cases per 100,000 persons, which was
most likely a vast underestimation even in countries like the USA [6]. More recently, the
number of cases and associated deaths has again increased in several industrialized countries,
reflecting a shortcoming in current vaccination strategies.
Two types of pertussis vaccines (PVs) are currently available: the first-generation whole-cell
vaccines (wPV) and the more recent acellular vaccines (aPVs). While the efficacy of wPV
(Table 1) has been demonstrated to be ≥94% after three administrations [7], the occurrence of
adverse local and systemic events along with difficulties in production consistency leads to the
development of aPVs in the 1980s, currently composed of one to five purified key antigens
(Table 2). All available aPVs are combined with tetanus and diphtheria toxoids. Several are
also formulated with hepatitis B, inactivated polio, and Haemophilus influenza B polysaccharide
[8]. The aPVs clearly have an improved safety profile over wPV, and their short-term efficacy
after three administrations was estimated to be 67–70% up to 84%, even those containing three
or five B. pertussis components [8]. This value was recently confirmed in a systematic review of
meta-analysis data focusing on the short-term protective effect of currently available childhood
pertussis vaccines [9]. Because of their improved safety profiles and similar efficacies, most
Table 1. List of whole cell pertussis vaccine manufacturers or distributors.
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Name of aPVs Composition1 Manufacturers/Distributer
2Acel-Imune (PT, FHA, PRN, FIM) +DT+TT Wyeth Pharmaceutics (USA)
2Acelluvax
(Triacelluvax)
(PT, FHA, PRN) +DT+TT Chiron Vaccines (USA)
3Adacel (PT, FHA, PRN, FIM) +DT+TT Sanofi Pasteur
4Boostrix-3 (PT, FHA, PRN) +DT+TT Sanofi Pasteur
BSc-1 (PT) Biocine Sclavo
CLL-3F2 (PT, FHA, FIM) Sanofi Pasteur (Canada)
Certiva (PT)+DT+TT Baxter Laboratory
Daptacel (Tripacel) (PT, FHA, PRN, FIM) +DT+TT Sanofi Pasteur
5DTaP-HB-IPV-Hib PT, FHA, PRN, FIM) +DT+TT + HB + IPV + Hib MGM Vacines Co (Merck/Sanofi)
62HCPDT (PT, FHA, PRN, FIM) +DT+TT Sanofi Pasteur (Canada)
Infanrix (PT, FHA, PRN) + DT+TT Glaxo Smith Klein (Rixensant, Belgium)
7JNIM-7 (PT) Japan Nat Inst of Healthy
LPB-3P (PT, FHA, PRN) Wyeth Lederle Vaccines and Pediatric
(Germany)
MIch-2 (PT, FHA) Michigan Department of Public Health
8NIH-6 (PT, FHA) Japan Nat Inst of Healthy
9Pentavac (PT, FHA, PRN, FIM) +DT+TT + HB + IPV + Hib Sanofi Pasteur (France)
Por-3F2 (PT, FHA, FIM) Speywood (Porton) Pharmaceuticals
10Repevax (PT, FHA, PRN, FIM) +DT+TT + IPV Sanofi Pasteur
SSVI-1 (PT) Swiss Serum and Vaccine Institute
11SKB-2 PT, FHA) +DT+TT SmithKline Beecham Biologicals
Triavax (PT, FHA) +DT+TT Sanofi Pasteur (France)
Tripedia (PT, FHA) +DT+TT Sanofi Pasteur (USA)
1Quantitative difference can be found in the aPV compounds formulations.
2No longer available (as of 2013).
3A 3-in-1 vaccine, differ from Infanrix by containing reduced quantities of PT (8 μg) + FHA (8 μg) + PRN (2,5 μg) +
DT (2.5 lf) + TT (5lf). Licensed for use in person with 4 yr age or older. In the USA 10-60 yr older.
4 A 3-in-1 vaccine approved for individuals aged ≥10 yr including those aged ≥65 yr.
5The 6-in-1 vaccine is given to babies as a series of 3 doses. The first dose is given at 2 months of age, the second at
4 months, and the third at 6 months. The vaccine is given at the same time as other childhood immunizations.
6Used in Pentacel and Pediacel.
7HCPDT is the “hybrid” formulation of Tripacel, evaluated in 1993 Stockholm trial.
8JNIH-6 and 7 were the aPV used in the 1986 Swedish trial.
9The 5-in-1 vaccine was used in the UK for many years. In late September 2017 the UK replaced it with a 6-in-1 vaccine for
all babies born on or after 1st August 2017. Both vaccines give protection against diphtheria, tetanus, whooping cough
(pertussis), polio and Hib disease (Haemophilus influenzae type b).
10A 3-in1 vaccine indicated for persons from 3 years of age as a booster following primary immunizations.
11SKB-2 was an experimental two-company DTaP evaluated in the 1992 Stockholm trial.
Abbreviations: PT, pertussis toxin; FHA, phytohemagglutinin; PRN, pertactin; FIM, fimbriae (mixture of FIM-2 and
FIM-3); TT, tetanus toxoid; DT, diphtheria toxoid, HB, Hepatitis B; IPV, Inactived Polio; Hib, Haemophilus influenzae type b.
Table 2. Source and composition of acellular pertussis vaccines studied and producers.
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developed countries have replaced wPV with an aPV. Globally, wPVs are still the most used
vaccines due the higher cost of aPVs, which are difficult to afford in resource-poor countries.
Although the vaccines together have saved millions of people since its introduction, it has been
estimated that their effectiveness appears to decrease between 2 and 10% per year [1, 10]. This
rate of decrease has been observed in countries that continue to administer wPV. Yet, it has
become apparent that the immunity induced by aPV declines substantially faster than that
induced by wPV [11, 12], which led the WHO to recommend that countries considering a
switch from wPV to aPV should expect further guidance [4]. Multiple studies, both epidemio-
logical and serological, have confirmed that immunity wanes rapidly after the aPV booster at
age 4–6 years and the preadolescent dose at age 10–12 years [13–18]. Nonetheless, it appears
that the waning immunity induced by aPV, or wPV, is not the only reason for the observed
resurgence in pertussis infections.
Another possible mechanism is asymptomatic transmission. Mathematical modeling of the
incidence rates of pertussis in the USA and UK supports a role for undetectable transmission
in the recent increase cases [19]. The potential for an essentially silent transmission is also
supported by observations in a baboon model recently developed for studying B. pertussis
infections. Vaccinations with aPV did not prevent transmission of B. pertussis. Virulent
B. pertussis continued to establish infections in animals vaccinated with either aPV or wPV,
even though both vaccines protected against disease. A major difference observed between
the two vaccines was that infections cleared more rapidly in wPV-vaccinated baboons [20].
All vaccinated animals showed a lower total bacterial load compared to naïve animals
suggesting that both vaccines have a positive impact to limit the progression of an infection.
Yet, it appears that this impact may not be sufficient to control the circulation of B. pertussis
within a population and could lead to the generation of vaccine escape mutants, which have
indeed been observed in several countries where aPV is in use. A likely explanation is the
observed increase in the isolation of strains not producing pertactin, due to selective pres-
sure [21]. Conversely, there is no apparent major difference in the pathogenesis of whooping
cough in children infected with pertactin-deficient strains compared to pertactin-producing
strains. This indicates that pertactin is not required for infection by B. pertussis or for the
development of the disease, suggesting a role of pertactin in the immune response following
vaccination.
In contrast to vaccination with either aPV or wPV, a natural infection by B. pertussis is able to
induce sterilizing immunity in baboons [20]. This fact is intriguing since studies in human have
shown that infection-induced immunity is longer lived than vaccine-induced immunity [22],
although probably not lifelong as reinfections have been reported to occur. While the second
attacks are very rare, they are usually much milder than the primary infections [23]. Since
B. pertussis is strictly a mucosal pathogen, it is conceivable that its restricted localization could
influence the immunity induced from a natural infection. Although the protective role of
mucosal immunity has so far attracted little attention, it may contribute to the differences
observed between the protection obtained by a vaccine and a natural infection. These observa-
tions suggest that a vaccination approach that more closely mimics a natural infection without
resulting in disease may be more successful to ultimately control pertussis.
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Such a vaccine is currently under development based on a live attenuated B. pertussis strain.
Named BPZE1, it has been genetically modified to affect the activity of three different toxins
such that they are absent, inactive, or minimally active [24]. This strain has been documented
to be safe in preclinical models and genetically stable over at least 1 year of continuous
passaging in vitro and in vivo in mice [25]. It can induce a strong protection against challenge
infections after a single intranasal administration, which lasted at least for up to 1 year. This
contrasts with the protection conferred by aPV that can begin to wane after only 6 months. The
strain BPZE1 has successfully completed a Phase I clinical trial that showed its safety profile in
young male volunteers with a single intranasal dose of up to 107 colony-forming units
suspended in 100 μl. This trial also showed that BPZE1 can transiently colonize the human
nasopharynx and induce B. pertussis-specific antibody responses in all colonized individuals.
At 6 months, follow-up studies measured antibody titers against all antigens tested to be at
least at the same level as detected at 1 month postvaccination. One concern with the trail was
the observation that not all subjects showed colonization by BPZE1, even at the highest dose
tested, since colonization was found to be essential for the induction of an immune response. A
possible reason of the absence of colonization in some individuals may have been their prior
contact with wild-type B. pertussis, which could have prevented a response to the vaccine.
Consistent with this hypothesis is the detection of preexisting antibody titers in the non-
colonized individuals that were significantly higher than the pre-vaccination titers of individ-
uals that displayed colonization, especially against pertactin. Additional studies are needed to
test the influence of a prior exposure to wild-type B. pertussis on BPZE1 colonization and to
eliminate the possibility for a previously imperceptible subclinical disease. New clinical trials
are in progress to test the hypothesis that the presence of preexisting antibodies prevents
colonization by the vaccine strain and to determine if their activity can be neutralized by
increasing the vaccine dosage.
Realistically, it would require many more years of research and regulatory approval before a
new pertussis vaccine could be available for general use. In the interim, efforts are being made to
optimize the application of current vaccines. A promising observation is the protection afforded
to newborns, less than 2 months of age, from the immunization of their mothers with aPV
during the 28–38th week of gestation. In a recent pertussis outbreak in the UK, the effectiveness
of this vaccination schedule was shown to be greater than 90% [26]. Several countries have now
made recommendations for providing aPV during pregnancy. However, many issues remain
unresolved. For example, the impact of maternal immunization on the immune responses in
infants following their primary vaccination is unclear. Several studies have observed a reduction
in the primary antibody response to B. pertussis antigens following a maternal vaccination [27].
Another issue is the observation that the adoptive caring immunity is effective to prevent
disease but does not prevent pertussis infections in neonates [28]. This suggests that the
maternal levels of preexisting pertussis-specific antibodies cannot transfer complete protec-
tion against infection. The maternal immune system can be activated in response to pertussis
and generates a recall response from memory B cells that increases the levels of milk IgA, but
the clinical relevance remains to be determined. Lastly, in a mouse model, challenge studies
also have shown that antibodies resulting from maternal vaccinations interfere with the
functionality of antibodies induced from a subsequent vaccination [29].
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2. Resurgence, vaccine design, and new targets
In 2008, there was an estimated incidence of 16 million cases of pertussis infection worldwide
that resulted in approximately 195,000 children deaths, making pertussis one of the leading
causes of vaccine-preventable deaths in children under 5 years of age [30, 31]. Most of pertussis
deaths occur in developing countries. However, pertussis has not only persisted in countries
with high vaccination coverage but has resurged with a number of epidemic episodes being
recorded [32–34]. The resurgence of pertussis as a deadly childhood disease is a major public
health concern that reflects changes in its epidemiology but is also affected by a growing
attitude among parents to delay or even refuse vaccination of their children, which highlights
the urgent need for new integrated approaches to control the spread and impact of whooping
cough. Several explanations have been presented to enlighten the resurgence of pertussis
disease over the past few decades in which most of them is associated with the aPVs currently
in use: (i) the decrease of vaccine effectiveness over time (declining immunity) [35, 36], (ii) the
selection of mutants that can escape the immunity induced by a vaccine [37, 38], and/or
(iii) failure of the vaccine to induce sterilizing immunity to the pathogen that avoids transmis-
sion [20]. However, perhaps the most significant contributing factor is our relative lack of
understanding the basics of pertussis infection, immunity, and disease. We are still unsure of
which specific immune responses are protective against B. pertussis infection and disease in
humans and how to elicit protective responses through vaccination.
To address the resurgence, new vaccination strategies have been explored such as the “cocoon-
ing strategy” and maternal immunization. Cocooning refers to the vaccination of mothers and
others with direct contact to newborns and infants. Cost-effective cocooning would be difficult
to implement since a successful program requires a very high number of contacts be vacci-
nated to attain a significant impact on the incidence of severe infant pertussis [39]. Currently,
there is a growing evidence for effectiveness of immunization of women during pregnancy
rather than during the immediate postpartum period. This approach has been found to be
more cost-effective than cocooning with a level of vaccine effectiveness against infant deaths
that reach an estimated 95% [27]. Alongside the vaccination of contacts, an alternative option
under consideration is to advance the vaccination schedule for newborns to 6–8 weeks of age.
However, this approach still does not provide protection to infants during their most suscep-
tible period for potentially deadly pertussis infections. A missing element to refinements in the
application of available vaccines is an improved surveillance for pertussis. Improvements in
the detection of infections and the immune response can positively contribute to evaluations
on vaccine efficacy that will help advance our understanding of performance and duration of a
pertussis vaccine to provide protection in the field.
Since the 1950s, the toxicity of traditional wPV has been associated with the presence of lipo-
polysaccharides (LPS), the major constituents of the bacterial outer membranes. To improve on
traditional wPVs, the Butantan Institute in Brazil recently produced a wPV with reduced quan-
tities of LPS that removed ≥80% of the endotoxin-related toxicity in comparison to traditional
wPV production methods using a chemical extraction of lipo-oligosaccharide (LOS) from the
outer membrane. The process maintained the main protective immunogens as well as the
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integrity of the bacteria in the vaccine [40]. A major challenge over the next few years will be the
implementation of a reproducible process that can produce consistent lots under good manu-
facturing practice conditions.
In recent years, extensive research efforts have elucidated that natural infections and immuni-
zations with wPVs predominantly induce IFN-γ-secreting T-helper 1 cells (Th1) and IL-17-
secreting Th17 cells [41–44]. By contrast, it has been shown that aPVs induce a qualitatively
different immune response, characterized by the induction of Th2 immunity [39, 43–45]. This
difference in the immune response, along with the chemical inactivation of the pertussis toxin
antigen in aPVs, may account for the apparent lack of aPV protection against colonization by
subsequent B. pertussis infections and suboptimal T-cell priming that has been observed as a
reduction in the efficiency for the generation of an immune memory repertoire.
Since current aPVs mainly elicit a Th2 response, several solutions have been proposed to
improve the Th1/Th17 responses. One possibility is to combine these vaccines with Th1-
driving adjuvants, at least for the priming doses [46, 51]. The development of such a candidate
vaccine based on a single-immunization platform consisting of three immune stimulators is in
progress [47], namely, (i) host defense peptides, (ii) polyphosphazenes (a family of inorganic
molecular hybrid polymers based on a phosphorus-nitrogen backbone substituted with organic
side groups with very diverse properties), and (iii) the synthetic oligonucleotides containing
CpG-ODN (oligodeoxynucleotides) combined with poly(I:C), (polyinosinic-polycytidylic acid)
an agonists of Toll-like receptor 9 (TLR9). This last immune stimulatory compound associated
with dacarbazine, a therapeutic agent, has been successfully used to promote antitumor immu-
nity [48].
In the case of pertussis, the inclusion of these immune stimulators resulted in a humoral
immune response from a single application in neonatal mice and pigs that was 100- to 1000-
fold stronger than a licensed aPV [47]. The onset of immunity occurred more quickly with a
predominantly Th1 response. Importantly, immunity persisted for more than 2 years and
appeared to be highly effective even in the presence of maternal antibodies. To address the
contribution of chemically inactivating pertussis toxin to vaccine performance, a strain of
B. pertussis was engineered as a source for genetically detoxified Ptx for the formulation of a
new aPV. In Thai adolescents, its safety was like Adacel, a trivalent aPV combined with
diphtheria and tetanus compounds produced by Sanofi Pasteur (see Table 2) with an
improved induction of neutralizing antibodies against PTx [47].
Substantial evidence has been accumulated in the last 2 years that immunity induced by aPVs
is much shorter lived than immunity induced by wPV [10]. Additionally, using refined tech-
niques of peptide microarray, it has been demonstrated that qualitative differences within the
humoral response of individuals vaccinated with wPV and aPVs exist. Using a microarray
technique, it was shown that animals immunized with wPV recognize qualitatively a major
number of B epitopes in the PTx than mice immunized with aPV [49]. Another study using a
similar approach compared the recognition pattern of sera from children immunized with
different pertussis vaccines (17 B. pertussis proteins) and concluded that 11% of the individuals
displayed a private humoral response [50]. All these studies are important to guide the rational
development of new vaccines.
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3. Difficulties with vaccine reformulation
While adults and adolescents normally only experience mild symptoms from a pertussis
infection, they are the usual source of infection for neonates, and adoptive maternal immunity
does not appear to prevent pertussis in neonates. In a study that compared the specific immune
response in mothers of neonates diagnosed with pertussis and mothers of control children [28],
preexisting pertussis-specific antibodies were insufficient for protection suggesting that memory
B cells play a major role in the adult defense, which is not transferred to neonates. To provide
newborns with protection, a new approach would be required, but to change the vaccine given
to infants in the first 2 years of life is a discouraging proposition. It would involve a large data set
for safety evaluation. Also, the pertussis vaccine is often combined into a multivalent formula
with components against other pathogens. Any change directed at improving effectiveness
against pertussis would require a recertification process that would impact a wide spectrum of
vaccines currently on the market.
More importantly, it would be unethical to conduct formal efficacy studies for new vaccines/
formulations that included a non-vaccinated control group. Considering the epidemiological and
serological studies that show a rapid decline in immunity after the recommended aPV boosters at
ages 4–6 and 10–12 years [13, 15, 16, 18], an intensive focus is being given on the booster vaccines
given to preschool-age children and adolescents. However, even for a new booster vaccine, the
regulatory pathway is unclear. A classical efficacy study would have to compare a new vaccine
with a currently accepted one to show non-inferiority or superiority. Such studies would be expen-
sive and require a long evaluation period considering that the current vaccines are effective for the
first couple of years after administration.
Ideally, licensing authorities could present new approaches to evaluate the efficacy of a new
vaccine. Alternatives include a greater reliance on the use of protection data obtained from
animal studies [52]. The newly developed baboon model could provide in-depth serological
data on the levels and duration of antibody titers, which can be verified in smaller human
challenge studies using circulating strains of B. pertussis. Safety profiles could also be gener-
ated from fewer participants if modifications simply involve an update in the components
with newer inactivation methods, such as genetic modifications. However, the greatest obsta-
cle is most likely to recruit manufacturers to participate in the development of a new pertus-
sis vaccine or booster. After the tremendous effort and expenditure invested to launch the
aPVs along with shifting priorities to new pathogens, major manufacturers are resistant to
shouldering multiple and simultaneous clinical development programs [52]. Physicians and
government health agencies will be critical to creating a new demand. Assistance from
academia and science funding agencies could assist vaccine development by conducting basic
research on the pathogenesis and immunology of pertussis along with preliminary clinical
trials [52]. All of this implies an enormous effort, but a new pertussis vaccine is needed. It is
unethical to continue to allow a vaccine-preventable disease to be incompletely controlled,
especially one that prejudices the very young people and disproportionately in less devel-
oped countries.
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4. Protecting versus vaccination during pregnancy
Since the resurgence of pertussis infection, several studies have shown that the main source
of infections in newborns and infants involved close-contact persons, mostly family members
[53, 54]. In the first attempt to reduce the incidence of pertussis infections, indirect protection
for the reduction of transmission rates was favored, the so-called cocooning strategy. In
response, some countries adapted their national immunization guidelines [53–55]. Another
study focused on the influence of vaccination rates among siblings and vaccination rates
among mothers showed that the provided protection rates are comparable [56, 57]. In contrast,
a recent study on the effect of cocooning infants younger than 6 months of age did not detect
any reduction in pertussis cases [57]. Besides that, it is not yet clear and has created some
controversy if cocoon strategies are cost-effective or even prevent infections [38, 58]. Even in
the absence of definitive proof, it is still advisable for recent mothers to know their immuniza-
tion status as well as those of all potentially close-contact individuals, all of whom can play a
critical role in the potential transmission of pertussis to a newborn.
Another means to reduce the rate of pertussis transmission to neonates and young infants is
the practice of providing pertussis vaccinations during pregnancy. This has become an impor-
tant strategy in many countries in the absence of vaccines licensed for use before the age of
6 weeks and unknown effectiveness of cocooning strategies [53, 59–61]. The observation of the
transplacental transfer of maternal anti-pertussis antibodies to the fetus led health authorities
to first recommend the use of pertussis vaccinations during pregnancy in 2011 [62–64]. In the
USA, a maternal vaccination was first recommended after gestational week 20 that was later
shifted to a window between weeks 27 and 36 [65]. This recommendation has been adopted by
both Switzerland and the UK [64].
Early studies showed that vaccination with Tdap vaccines during gestational week 27–30 + 6
was associated with the highest levels of IgG in umbilical cord blood when compared to
vaccination beyond gestational week 31 [59], according to one of the most potent virulence
factors of pertussis PTx. A recent study supports these data by showing that the maternal
vaccination with Tdap early in the second trimester significantly increased neonatal antibodies
at birth in comparison with neonates born from mothers vaccinated in the third trimester [61].
All in all, the antenatal vaccination campaign in the UK achieved a vaccine coverage of 60%
with >90% effectiveness [66, 67]. A UK study conducted after initiating maternal vaccinations
identified a large reduction in the number of confirmed cases of pertussis infection reported as
the cause for a hospital admission that was especially notable for infants younger than 3 months
of age [66].
From this campaign, the question arose as to whether a vaccination early in pregnancy might
adversely affect the immune response in an infant to vaccinations after birth. Some studies
showed that antibody concentrations at birth did not interfere with the immune response to
further immunizations after birth [68]. However, it is known that maternally derived antibodies
can interfere with the immune response in an infant vaccinated with the same vaccine [68],
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which was detected after DTaP1 (administered to children under 7 years of age) vaccination
[69]. Maternal antibodies were also shown to interfere with the antibody response to the
primary vaccination administered during infancy to children born to Tdap1 (administered to
older children and adults)-vaccinated mothers [62, 70]. Interestingly, a mouse model showed
that the vaccination of infant mice reduced the protective functions of maternally derived
antibodies in vitro and in vivo [29]. A study that focused on vaccinations with Repevax, a five
component aPV combined with tetanus, low-dose diphtheria, and inactivated polio vaccine
(Sanofi Pasteur), detected a significant attenuation of pertussis antibodies in infants whose
mothers were vaccinated with Repevax during pregnancy [71]. Together with the diminished
protection afforded by aPVs, recent findings suggest that the efficacy of current vaccines
should be maximized by prenatal vaccination followed by boosting. It is important to continue
studies to determine the functionality of maternal antibodies resulting from vaccinations
during pregnancy and infant antibodies generated from subsequent vaccinations to better
understand the potential for cross interference to design alternative vaccination strategies.
5. Conclusion
It is irrefutable that the worldwide incidence of severe pertussis cases is rising. Nearly 90% of
all instances of deaths caused by pertussis occur in infants younger than 4 months of age and
are caused by fatal pertussis pneumonia due to PTx activity [72], which highlights the need to
inhibit PTx during an acute infection. Over the past few years, the scientific community has
responded by initiating studies focused on a better understanding of virulence factors, like
PTx, transmission dynamics, and host immune reactions, which can provide a foundation for
the generation of a new vaccine but can also guide improvements in the use of current
vaccines. It is clear that a control of pertussis requires a durable protection against disease
and disruption of transmission. The two types of vaccines available, wPV and aPV, are effec-
tive in preventing the disease, but the immunity developed by each wane over time, even more
rapidly with aPV, which should encourage countries in which wPV is still in use, not to switch
to aPV. Further, transmission from vaccinated individuals is possible since B. pertussis can still
colonize their respiratory tracts. Improvements to both types are in development, but it will be
several years before their widespread use. In the interim, expansions in the use of the current
vaccines have been proposed. Cocoon vaccination programs, which are controversial in their
effectiveness, rely on generating herd immunity to protect young infants by vaccinating indi-
viduals with close contact. In contrast, immunization with aPV during pregnancy can reduce
the incidence of severe and deadly pertussis in neonates. However, there are concerns that the
antibodies raised from the maternal immunization can interfere with the immune response in
the child to their primary vaccination. All approaches under development would benefit from
1
DTaP, Tdap, and Td are all similar vaccines, given for the same diseases at different times of life. Depending on the age,
certain amounts of vaccine components are administered. Typing uppercase and lowercase letters denotes the component
of the vaccine and the quantities in it. Uppercase letters in abbreviations denote undiluted doses of diphtheria (D), tetanus
(T), and pertussis (P) toxoids. The lowercase letters d and p denote reduced doses of diphtheria and pertussis toxoids used
in formulations for adolescents and adults. The letter a in the DTaP and Tdap vaccines means acellular.
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a more detailed surveillance program to determine the rates of symptomatic and asymptom-
atic infections as well as an examination of the genetic diversity of B. pertussis strains in
circulation to better understand methods to prevent the impacts of infection.
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